Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
Go back to Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models| GALMED PHARMACEUTIC (NASDAQ: GLMD) | Delayed: 3.83 -0.05 (1.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.88 | 52 Week High | $9.70 | |||
| Open | $3.81 | 52 Week Low | $2.78 | |||
| Day High | $3.96 | P/E | N/A | |||
| Day Low | $3.74 | EPS | $0.00 | |||
| Volume | 14,848 | |||||
